Under the recently proposed framework for presymptomatic ALS research (Benatar et al., 2019), the presymptomatic C9+ carriers in this study appeared to be in a very early stage, and levels of biomarkers of axonal degeneration remained low. The gene discussed is C9; the disease is amyotrophic lateral sclerosis.